In this episode of the Innovations and Clinical Implementation podcast recorded at LongevityFest 2025, hosts Dr. Lexi Gonzales and Tom Blue explore the frontier of liposomal peptide therapy with Dr. Christopher Shade—the founder and CEO of Quicksilver Scientific and an internationally recognized expert on environmental toxicants who pioneered the use of lipid-based nanoparticle delivery systems. Dr. Shade argues that "inflammaging" and endotoxemia often block the efficacy of standard hormone therapies by downregulating receptors, and he advocates for using specific liposomal peptides like BPC-157, KPV, and Thymulin to break these inflammatory cycles and reverse "fatty thymus." The conversation details how intraoral nanoliposomes utilize membrane fusion to achieve high intracellular uptake, offering practitioners a compliant, scalable method to transition from symptom-chasing "personalized medicine" to upstream "precision medicine" that rapidly seals the gut and resets immune resilience.
For access to episode resources, click HERE.
Redefining Medicine